Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial

Daniel A. Geller, Karen Dineen Wagner, Graham Emslie, Tanya Murphy, David J. Carpenter, Erica Wetherhold, Phil Perera, Andrea Machin, Christel Gardiner

Research output: Contribution to journalArticle

141 Scopus citations


Objective: To assess the efficacy and safety of paroxetine for the treatment of pediatric obsessive-compulsive disorder. Method: Children (7-11 years of age) and adolescents (12-17 years of age) meeting DSM-IV criteria for obsessive-compulsive disorder were randomized to paroxetine (10-50 mg/day) or placebo for 10 weeks. The primary efficacy measure was change from baseline in the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) total score at week 10 last observation carried forward end point. Safety was assessed primarily through adverse event monitoring. Results: A total of 207 patients were randomized to treatment. Of these, 203 were included in the intention-to-treat population. Adjusted mean changes from baseline at week 10 observation carried forward end point in CY-BOCS total score for patients receiving paroxetine and placebo were -8.78 (SE = 0.82) and -5.34 points (SE = 0.77), respectively. The adjusted mean difference, -3.45 in favor of paroxetine, was statistically significant (95% confidence interval = -5.60 to -1.29, p = .002). Adverse events were generally mild to moderate in intensity. A total of 10.2% (10/98) of patients in the paroxetine group and 2.9% (3 of 105) in the placebo group discontinued treatment because of adverse events. Conclusions: Paroxetine is an effective and generally well-tolerated treatment for obsessive-compulsive disorder in children and adolescents.

Original languageEnglish (US)
Pages (from-to)1387-1396
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Issue number11
StatePublished - Nov 2004



  • Obsessive-compulsive disorder
  • Paroxetine
  • Pediatric
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this